Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PBI-4050 in Type 2 Diabetes Mellitus Patients With Metabolic Syndrome

NCT03081598 is registered in ClinicalTrials.gov with Liminal BioSciences Ltd. as lead sponsor.

NCT NCT03081598
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03081598 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PBI-4050 in Type 2 Diabetes Mellitus Patients With Metabolic Syndrome
Lead sponsor
Liminal BioSciences Ltd.
Phase
Phase 2
Overall status
Terminated
Start date
May 29, 2017
Completion date
September 6, 2018
Enrollment
104 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

metabolic syndrome, type 2 diabetes mellitus